DDInter786 DDInter1676
Fostemsavir is the phosphonooxymethyl prodrug of temsavir, a novel HIV-1 attachment inhibitor. It binds to and inhibits the activity of gp120, a subunit within the HIV-1 gp160 envelope glycoprotein that facilitates the attachment of HIV-1 to host cell CD4 receptors - in doing so, temsavir prevents the first step in the HIV-1 viral lifecycle. The discovery of gp120 as a potential target of interest in the treatment of HIV-1 infection is relatively recent, and was born out of a desire to find alternative target proteins (i.e. mechanistically orthogonal therapies) for the treatment of HIV-1 patients with resistant infections. Fostemavir is the first attachment inhibitor to receive FDA approval, granted in July 2020 for use in combination with other antiretrovirals in highly treatment-experienced patients with multidrug-resistant HIV-1 infection whom are failing their current therapy.[L14867,L
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Fostemsavir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Aminoglutethimide
Fostemsavir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Brigatinib
Fostemsavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Quinine
Fostemsavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Triclabendazole
Fostemsavir {u} may lead to a major life threatening interaction when taken with {v} Ribociclib
Fostemsavir {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Aminoglutethimide
Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Fostemsavir may cause a moderate interaction that could exacerbate diseases when taken with Quinine
Fostemsavir may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Fostemsavir may lead to a major life threatening interaction when taken with Ribociclib
Fostemsavir may lead to a major life threatening interaction when taken with Macimorelin